Microbial Data Analyses ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  20.7% 15.2% 5.8% 5.4% 9.0%  
Credit score (0-100)  6 13 38 41 26  
Credit rating  B BB BBB BBB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  111 0 350 216 0  
Gross profit  86.0 162 271 136 64.9  
EBITDA  86.0 162 271 136 64.9  
EBIT  86.0 162 271 136 64.9  
Pre-tax profit (PTP)  84.9 160.4 150.6 135.2 63.7  
Net earnings  66.2 125.1 210.3 105.0 49.7  
Pre-tax profit without non-rec. items  84.9 160 270 135 63.7  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  67.2 192 443 550 599  
Interest-bearing liabilities  0.0 0.0 40.0 40.0 40.0  
Balance sheet total (assets)  139 218 542 636 660  

Net Debt  -139 -59.7 -58.2 -19.0 -6.8  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  111 0 350 216 0  
Net sales growth  0.0% -100.0% 0.0% -38.2% -100.0%  
Gross profit  86.0 162 271 136 64.9  
Gross profit growth  0.0% 88.3% 67.5% -49.7% -52.4%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  139 218 542 636 660  
Balance sheet change%  0.0% 57.3% 148.6% 17.3% 3.8%  
Added value  86.0 161.9 271.2 136.3 64.9  
Added value %  77.5% 0.0% 77.5% 63.1% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 -1.0 0.0 -1.0 -2.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  77.5% 0.0% 77.5% 63.1% 0.0%  
EBIT %  77.5% 0.0% 77.5% 63.1% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  59.7% 0.0% 60.1% 48.6% 0.0%  
Profit before depreciation and extraordinary items %  59.7% 0.0% 60.1% 48.6% 0.0%  
Pre tax profit less extraordinaries %  76.5% 0.0% 77.0% 62.5% 0.0%  
ROA %  62.0% 90.8% 71.3% 23.1% 10.0%  
ROI %  127.9% 124.8% 80.3% 25.4% 10.6%  
ROE %  98.5% 96.4% 66.2% 21.2% 8.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  48.5% 88.2% 81.6% 86.4% 90.8%  
Relative indebtedness %  64.4% 0.0% 28.5% 39.9% 0.0%  
Relative net indebtedness %  -60.6% 0.0% 0.4% 12.6% 0.0%  
Net int. bear. debt to EBITDA, %  -161.2% -36.9% -21.5% -13.9% -10.5%  
Gearing %  0.0% 0.0% 9.0% 7.3% 6.7%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 7.5% 2.8% 3.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.9 8.5 5.4 7.4 10.9  
Current Ratio  1.9 8.5 5.4 7.4 10.9  
Cash and cash equivalent  138.7 59.7 98.2 59.0 46.8  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 149.4 152.4 0.0  
Trade creditors turnover (days)  456.3 0.0 0.0 0.0 0.0  
Current assets / Net sales %  124.9% 0.0% 154.9% 294.1% 0.0%  
Net working capital  67.2 192.4 442.7 549.7 599.3  
Net working capital %  60.6% 0.0% 126.4% 254.2% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0